The Hindu Business Line : GSK Pharma launches two new vaccines

Mumbai, Feb. 1 GlaxoSmithKline Pharmaceuticals Ltd (GSK) has brought into the country Boostrix and Infanrix, two of its new innovative vaccines indicated for Diphtheria, Tetanus and acellular Pertussis (DTP).

Unlike traditional vaccines, acellular vaccines provide more comfort to children due to reduced pain, fever and swelling, a GSK note said.

Both products are priced at Rs 699 and will be imported from the GSK Biologicals plant in Belgium, a source familiar with the development told Business Line. Acellular DTP vaccines are part of routine immunisation in over 100 developed and developing countries, the company added.

Infanrix is indicated for childhood immunisation against DTP for newborns from the sixth week. And when combined with Hepatitis B vaccines it reduces the number of pricks and visits to the doctor, the note said.

Boostrix is administered to children above seven years, adolescents and adults and helps boost the waning immunity against DTP.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Glenmark ends drug deal with Merck

GSK Pharma launches two new vaccines

TVS, Bajaj patent hearing continues

$7.7 b raised via FCCBs in 2007, despite curbs

Moody’s puts Tata Chem on watch

Technopak ties up with Vertebrand

Lanco achieves financial closure for 2 road projects

Aurobindo drug gets US FDA nod

ONGC may tie up with Norwegian co for green tech

Corus buy: ‘Innovations in funding saved millions of dollars’